Pharmacokinetics of L-dopa in patients with Parkinson's disease.

Suppr

超能文献

作者信息

Mena M A, Muradas V, Bazan E, Reiriz J, de Yebenes J G

出版信息

Adv Neurol. 1987;45:481-6.

PMID:2950730

Abstract

摘要

相似文献

Pharmacokinetics of L-dopa in patients with Parkinson's disease.

Adv Neurol. 1987;45:481-6.

[L-dopa therapy of parkinson syndrome].

Nervenarzt. 1985 Feb;56(2):57-68.

[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].

Neurologia. 1997 Apr;12(4):145-56.

Treatment of Parkinson's disease.

Curr Opin Neurol Neurosurg. 1993 Jun;6(3):339-43.

[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].

MMW Munch Med Wochenschr. 1976 May 14;118(20):653-6.

[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].

Rev Neurol (Paris). 1977 Aug-Sep;133(8-9):445-54.

Parkinson's disease: new treatments.

Compr Ther. 1981 Apr;7(4):38-44.

[Long-term problems of levodopa therapy in Parkinson disease].

Schweiz Med Wochenschr. 1987 Mar 7;117(10):347-53.

[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].

Rinsho Shinkeigaku. 1976 Jul 1;16(7):511-9.

A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.

Can J Neurol Sci. 1987 Nov;14(4):576-80.

引用本文的文献

Neurodegenerative Etiology of Aromatic L-Amino Acid Decarboxylase Deficiency: a Novel Concept for Expanding Treatment Strategies.

Mol Neurobiol. 2024 May;61(5):2996-3018. doi: 10.1007/s12035-023-03684-2. Epub 2023 Nov 13.

Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.

J Neural Transm (Vienna). 2021 Jan;128(1):27-36. doi: 10.1007/s00702-020-02267-y. Epub 2020 Nov 2.

The role of 3-O-methyldopa in the side effects of L-dopa.

Neurochem Res. 2008 Mar;33(3):401-11. doi: 10.1007/s11064-007-9442-6. Epub 2007 Aug 24.

Concentration-effect relationship of levodopa in patients with Parkinson's disease.

Clin Pharmacokinet. 1995 Oct;29(4):243-56. doi: 10.2165/00003088-199529040-00004.

The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance.

Neurochem Res. 1993 Mar;18(3):325-30. doi: 10.1007/BF00969090.

Low catechol-O-methyltransferase activity in a Saami population.

Eur J Clin Pharmacol. 1994;46(3):231-5. doi: 10.1007/BF00192554.

The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.

Experientia. 1994 Oct 15;50(10):939-42. doi: 10.1007/BF01923483.

Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):149-61. doi: 10.1007/BF02816115.

The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.

Br J Pharmacol. 1990 Aug;100(4):743-8. doi: 10.1111/j.1476-5381.1990.tb14085.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验